Will the side effects of Pemetinib/Dabotan persist?

Pemigatinib (Pemigatinib), as a targeted drug, has received widespread attention due to its effectiveness in the treatment of cancers such as cholangiocarcinoma (CCA). However, many patients who receive pemetinib are often concerned about its side effects, especially whether these side effects will persist.

First, the side effects of pemetinib vary from individual to individual. Common adverse reactions include hyperphosphatemia, alopecia, stomatitis, diarrhea, etc. Some patients may also experience symptoms such as rash and fatigue. Although these adverse reactions are not uncommon in clinical practice, they are often controllable for most patients. With appropriate dosage adjustments and symptomatic treatment, patients can often effectively alleviate these discomforts. In addition, doctors will closely monitor the patient's response during treatment and make corresponding drug adjustments when necessary to reduce the incidence of side effects.

As for whether side effects will persist, the answer is not set in stone. Studies have shown that the adverse reactions caused by pemetinib are often more obvious in the early stages of treatment, and as treatment progresses, the side effects of many patients may gradually reduce or disappear. For example, after receiving pemetinib for a period of time, the patient's body gradually adapts to the effects of the drug, resulting in less frequent adverse reactions. In addition, some side effects will relieve themselves after stopping the drug, and the patient's body will gradually return to the state before treatment.

Of course, individual patients may experience ongoing side effects, which are often related to the patient's own medical condition, other underlying medical conditions, and other medications they are taking at the same time. Therefore, during the use of pemetinib, patients should maintain close communication with their doctors and promptly report any discomfort so that doctors can make timely adjustments and treatments.

Reference materials:https://go.drugbank.com/drugs/DB15102